Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omectatug
- Development stage
- Unknown
- Lead developer
- AskGene Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Omectatug (ASKB589) is a humanized recombinant IgG1 monoclonal antibody targeting claudin 18.2 (CLDN18.2), a tight junction protein frequently overexpressed in gastric, gastroesophageal junction (G/GEJ), and pancreatic cancers. Developed by AskGene Pharma and Jiangsu Aosaikang Pharmaceutical, omectatug binds with high affinity to CLDN18.2-expressing tumor cells, mediating potent anti-tumor activity through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The drug is currently in Phase III clinical development in China, evaluated in combination with chemotherapy (CAPOX) and PD-1 inhibitors (such as tislelizumab) as a first-line treatment for patients with CLDN18.2-positive advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on omectatug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omectatug.